Iron Oxide Nanoparticles Affects Behaviour and Monoamine Levels in Mice
- 39 Downloads
Iron oxide (Fe2O3) nanoparticles (NPs) attract the attention of clinicians for its unique magnetic and paramagnetic properties, which are exclusively used in neurodiagnostics and therapeutics among the other biomedical applications. Despite numerous research findings has already proved neurotoxicity of Fe2O3-NPs, factors affecting neurobehaviour has not been elucidated. In this study, mice were exposed to Fe2O3-NPs (25 and 50 mg/kg body weight) by oral intubation daily for 30 days. It was observed that Fe2O3-NPs remarkably impair motor coordination and memory. In the treated brain regions, mitochondrial damage, depleted energy level and decreased ATPase (Mg2+, Ca2+ and Na+/K+) activities were observed. Disturbed ion homeostasis and axonal demyelination in the treated brain regions contributes to poor motor coordination. Increased intracellular calcium ([Ca2+]i) and decreased expression of growth associated protein 43 (GAP43) impairs vesicular exocytosis could result in insufficient signal between neurons. In addition, levels of dopamine (DA), norepinephrine (NE) and epinephrine (EP) were found to be altered in the subjected brain regions in correspondence to the expression of monoamine oxidases (MAO). Along with all these factors, over expression of glial fibrillary acidic protein (GFAP) confirms the neuronal damage, suggesting the evidences for behavioural changes.
KeywordsBrain markers Demyelination Energy depletion Fe2O3-NPs Monoamines Neurobehaviour
The authors would like to acknowledge Sophisticated Analytical Instrument Facility, All India Institute of Medical science (AIIMS), New Delhi, for the technical assistance in transmission electron microscopy. The authors are also grateful to Mr. Monojit Bhattacharjee, Bharathiar University, Coimbatore, for his assistance in HPLC analysis. Vijayprakash Manickam acknowledges the UGC-BSR fellowship (UGC-BSR-No.F.7-25/2007) funded by UGC-BSR, New Delhi, India. We also thank the UGC-SAP DRS II (F-3-30/2013), DST FIST (SR/FST/LSI-618/2014) and DST-SERB (EMR/2014/000600), New Delhi, India for their partial financial assistance.
Compliance with Ethical Standards
Conflict of interest
The authors declare no conflict of interest.
All procedures performed in this study involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.
- 2.Weinstein JS, Varallyay CG, Dosa E, Gahramanov S, Hamilton B, Rooney WD, Muldoon LL, Neuwelt EA (2010) Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab 30:15–35CrossRefGoogle Scholar
- 22.Estelrich J, María JSM, Maria AB (2015) Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents. Int J Nanomed 10:1727–1741Google Scholar
- 25.Ekambaram P, Paul V (2003) Effect of vitamin D on chronic behavioral and dental toxicities on sodium fluoride in rats. Fluoride 36(3):189–197Google Scholar
- 33.Chen K, Cases O, Rebrin I, Wu W, Gallaher TK, Seif I, Shih JC (2006) Forebrain-specific expression of monoamine oxidase a reduces neurotransmitter levels, restores the brain structure, and rescues aggressive behavior in monoamine oxidase a-deficient mice. J Biol Chem 282:115–123CrossRefGoogle Scholar
- 37.Guo C, Sun L, Chen X, Zhang D (2003) Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regen Res 8:2003–2014Google Scholar
- 51.Xing Y, Samuvel DJ, Stevens SM, Dubno JR, Schulte BA, Lang H (2012) Age-Related Changes of Myelin Basic Protein in Mouse and Human Auditory Nerve. PLoS ONE 7:1–15Google Scholar
- 57.Lovinger DM (2008) Communication networks in the brain neurons, receptors, neurotransmitters and alcohol. Alcohol Res Health 31:196–214Google Scholar
- 63.Eisenhofer G, Finberg JP (1994) Different metabolism of norepinephrine and epinephrine by catechol-O-methyltransferase and monoamine oxidase in rats. J Pharmacol Exp Ther 268:1242–1251Google Scholar